Covid-19
The Covid-19 form was introduced for participants who had been admitted to the hospital for treatment of COVID-19. Since our last update, we have received 44 new forms (total number of forms 155). For each form completed, 50 euros will be reimbursed.
Cabotegravir
Data on injectable long-acting cabotegravir and/or long-acting rilpivirine treatment are now collected annually in two separate REDCap forms. Since our last update, we have received 57 forms (a total of 64 forms). We encourage you to fill out the next-injection forms for each injection. Reimbursement is based on a full year of follow-up, and we are interested in collecting as much data as possible.
MISTRAL
The MISTRAL study is progressing well. We are pleased to announce that there are now 17 sites open and 188 participants (from Belgium, Croatia, the Czech Republic, Denmark, Germany, Luxembourg, Poland, and the UK) enrolled in the study. 134 of the 188 participants are new MISTRAL participants and 54 of those are existing EuroSIDA participants. The aim is to enroll 1000 participants this year with at least 2 years of follow-up in 2024-2025.
So far, 8 virtual training sessions have been held and two more training sessions are planned. If you would like to participate in a training session, you can send an e-mail to the MISTRAL Secretariat office at mistral.rigshospitalet@regionh.dk.
For more information on the MISTRAL study click here.